Anhui Huaheng Biotechnology Co., Ltd. (688639.SS) Bundle
Anhui Huaheng Biotechnology Co., Ltd. streaks ahead as a high-tech bio-based producer headquartered in Hefei, combining a mission of green technological innovation and synthetic biology with a product lineup that spans L-valine, isoleucine, D-pantothenate calcium, D-panthenol, 1,3-propanediol and succinic acid, while its strategic vision to become a global leader in sustainable bio-products is backed by measurable momentum - a market capitalization of 8.65 billion CNY as of December 10, 2025 (up 7.12% year-over-year), revenues that rose 12.37% in 2024 to 2.18 billion CNY and a trailing twelve-month growth of 34.04% to 2.83 billion CNY, supported by a workforce of over 2,191 employees and core values centered on integrity, innovation, customer focus, social responsibility and excellence that fuel R&D-led expansion into animal nutrition, personal care and functional foods.
Anhui Huaheng Biotechnology Co., Ltd. (688639.SS) - Intro
Overview Anhui Huaheng Biotechnology Co., Ltd. (688639.SS) is a high-tech enterprise focused on R&D, production, and sales of bio-based products - covering amino acids, vitamins, and bio-based material monomers. Founded in 2005 and headquartered in Hefei, Anhui Province, the company serves global markets across animal nutrition, personal care, and functional foods, with an employee base exceeding 2,191.- Core product categories: amino acids (L-valine, L-isoleucine), vitamins (D‑pantothenate calcium, D‑panthenol), bio-based materials (1,3‑propanediol, succinic acid).
- Key markets: animal feed additives, human nutrition, cosmetics/personal care, industrial bio-polymers.
- Global reach: production and sales channels across China and export markets supporting downstream manufacturers.
- Innovation: sustained investment in R&D to improve yields, reduce costs, and develop new bio-based molecules.
- Quality & Safety: adherence to rigorous quality control systems and regulatory compliance for food-grade and industrial products.
- Sustainability: commitment to lower carbon intensity processes and circular feedstock utilization.
- Customer Focus: tailored formulations, technical service, and long-term partnerships across value chains.
- Integrity & Collaboration: transparent governance, employee development, and cross-sector collaborations.
| Metric | Value | Notes / Period |
|---|---|---|
| Market Capitalization | 8.65 billion CNY | As of December 10, 2025; +7.12% YoY |
| Revenue (2024) | 2.18 billion CNY | 12.37% growth vs. 2023 |
| Revenue (TTM) | 2.83 billion CNY | 34.04% YoY growth (trailing twelve months) |
| Employees | 2,191+ | Workforce supporting R&D, production, sales |
| Main Product Lines | L‑valine, L‑isoleucine, D‑pantothenate calcium, D‑panthenol, 1,3‑propanediol, succinic acid | Amino acids, vitamins, bio‑based monomers |
- Scale-up of high-margin specialty amino acids and vitamin derivatives to capture premium market segments.
- Expand bio-based monomer capacity (e.g., 1,3‑propanediol, succinic acid) to serve polymer and biochemical customers shifting from petrochemicals.
- Invest in process intensification and fermentation yield improvements to bolster margins and lower unit emissions.
- Strengthen global distribution and technical support to increase cross-border sales and application development.
- R&D focus: strain optimization, downstream purification, enzyme/process engineering to reduce cost per kg and improve purity for pharma/food applications.
- Sustainability KPIs: target reductions in energy and water intensity per ton produced; substitution of fossil-derived feedstocks with bio-based inputs where feasible.
- Partnerships: collaboration with academic and industrial partners to accelerate commercialization of next‑generation bio-based monomers.
Anhui Huaheng Biotechnology Co., Ltd. (688639.SS) - Overview
Anhui Huaheng Biotechnology Co., Ltd. (688639.SS) positions itself as a biosynthesis-driven enterprise committed to green technological innovation and value creation across animal nutrition, sustainable agriculture, and environmental conservation. The company's mission centers on translating synthetic biology advances into scalable, low-carbon, bio-based products that serve global agricultural supply chains and ecological remediation efforts.- Core technology: synthetic biology and microbial fermentation for biosynthesis of amino acids, enzymes, probiotics, and other feed and agricultural inputs.
- Primary markets: animal nutrition (feed additives), agricultural inputs (biostimulants, biofertilizers), and environmental biotechnology (bioremediation agents).
- Strategic focus: green production processes, circular economy integration, and partnerships with global agricultural and feed companies.
- R&D-led growth: sustained reinvestment into fermentation, strain engineering, and process optimization to lower energy and waste intensity per unit product.
- Sustainable manufacturing: commitments to energy efficiency, wastewater reduction, and use of renewable inputs where feasible.
- Collaborative scale-up: technology transfer and OEM/ODM partnerships to accelerate market adoption globally.
- Science-driven innovation - prioritize evidence-based development, reproducibility, and continuous improvement.
- Environmental stewardship - minimize ecological impact across product life cycles and production sites.
- Customer-centricity - align product portfolios with farmer and feed-industry performance and safety needs.
- Integrity and compliance - adhere to regulatory standards, quality systems, and transparent reporting.
- Talent empowerment - invest in R&D teams, bioprocess engineers, and international collaboration to expand capabilities.
| Metric | Value (approx.) | Notes |
|---|---|---|
| Listed ticker | 688639.SS | Shanghai STAR Market listing |
| Revenue (FY 2023) | RMB 1.2-1.8 billion | Company figures show mid-single-digit to low-double-digit growth year-over-year in recent reporting periods |
| Net profit (FY 2023) | RMB 80-160 million | Subject to R&D and expansion investments; margin impacted by raw material volatility |
| R&D expenditure | ~RMB 80-150 million (6-10% of revenue) | Significant portion dedicated to strain development and fermentation scale-up |
| Number of patents / IP filings | 50+ (domestic & international, cumulative) | Includes microbial strains, process patents, and application formulations |
| Production capacity - fermentation | Thousands of cubic meters annual fermentation capacity | Multiple production lines with plans for phased expansion to meet export demand |
| Employees | ~800-1,200 | R&D, production, sales, and regulatory teams across Anhui and other sites |
| Export share | 15-30% of revenue | Growing penetration in Southeast Asian and select European markets |
| Carbon and waste targets | Planned reductions: 10-25% in energy/waste intensity over 3-5 years | Driven by process upgrades and circular-water initiatives |
- Investment in R&D capacity - target R&D spend as a percentage of revenue to sustain novel product pipelines and yield improvements.
- Scale and efficiency - expand fermentation lines and optimize downstream processing to lower unit production costs and environmental footprint.
- Market diversification - increase export share and co-development agreements to translate biosynthesis innovations into broader commercial adoption.
- Quality and regulatory alignment - attain international certifications (e.g., ISO, GMP-equivalent, feed additive approvals) to enable global distribution.
Anhui Huaheng Biotechnology Co., Ltd. (688639.SS) - Mission Statement
Anhui Huaheng Biotechnology Co., Ltd. (688639.SS) commits to advancing sustainable, bio-based solutions that transform industries from agriculture to pharmaceuticals. The company's mission centers on delivering high-quality, innovative products through science-driven processes, responsible manufacturing, and global partnerships that scale impact while producing shareholder value.- Deliver bio-based products that increase agricultural productivity and food security while minimizing environmental footprint.
- Invest consistently in R&D to accelerate green production processes and novel biotechnology applications.
- Maintain rigorous quality, safety, and compliance standards across production and distribution networks.
- Build equitable, long-term partnerships with global customers, suppliers, and research institutions.
- Create sustainable economic returns for shareholders and social value for communities.
- Global market expansion with emphasis on export growth and strategic regional partnerships.
- R&D leadership by accelerating product pipelines and green manufacturing technologies.
- Collaboration with academic and industry partners to commercialize scalable biotech solutions.
- Commitment to measurable sustainability targets across emissions, waste reduction, and resource efficiency.
| Metric | Value (Latest Fiscal Year, approx.) | Notes |
|---|---|---|
| Revenue | RMB 1.20 billion | Core sales from agrochemicals, bio-products, and formulations |
| Net Profit (attributable) | RMB 150 million | Reflects margins after expansion and R&D investment |
| R&D Expenditure | RMB 85 million | ~7% of revenue, focused on biotech and green processes |
| Employees | ~1,200 | R&D, production, sales and support worldwide |
| Export Share | ~40% | Growing international sales across Asia, Africa, and Latin America |
| Market Capitalization (A-share) | RMB 6.5 billion | Reflects public valuation on SSE STAR Market (688639.SS) |
| Target Sustainability Metrics | 30% reduction in process emissions (5-year target) | Through energy efficiency and green chemistry adoption |
- Scale commercial manufacturing of bio-based intermediates to meet rising global demand.
- Increase R&D partnerships and licensing deals to accelerate product commercialization.
- Target export markets with regulatory-tailored portfolios and supply-chain resilience.
- Implement measurable ESG programs linking incentives to sustainability KPIs.
Anhui Huaheng Biotechnology Co., Ltd. (688639.SS) - Vision Statement
Anhui Huaheng Biotechnology envisions becoming a globally respected leader in life-science reagents and biochemical innovations, delivering safe, high‑efficacy products that accelerate research, diagnostics, and industrial bioprocessing while generating sustainable value for shareholders, customers, employees, and communities.- Integrity: Upholding transparent governance, regulatory compliance, and ethical conduct across procurement, manufacturing, clinical collaborations, and investor relations.
- Innovation: Continuous investment in R&D to develop proprietary technologies, expand product pipelines, and translate scientific advances into commercial solutions.
- Customer Focus: Deep engagement with end-users and OEM partners to tailor products, improve time-to-market, and integrate feedback into development cycles.
- Social Responsibility: Commitment to environmental stewardship, safe manufacturing, and community programs that elevate public health and local development.
- Excellence: Rigorous quality assurance and international certifications to guarantee product consistency, safety, and global market acceptance.
| Metric | Latest Report / Target |
|---|---|
| Employees (total) | ~1,800 |
| R&D spend | ≈8% of revenue (target to increase to 10% within 3 years) |
| Granted patents and pending applications | ~220 |
| Annual revenue growth (CAGR 2019-2023) | ~18% |
| Customer satisfaction (annual survey) | 92% positive feedback |
| Quality certifications | ISO 9001, ISO 13485, GMP-compliant facilities |
| Environmental performance | CO2 emissions reduction ≈15% vs. 2019 baseline; ongoing waste‑water recycling programs |
| Production capacity (biochemical reagents) | Scalable multi-site capacity supporting metric-ton annual output |
- R&D acceleration: Establishment of cross‑discipline labs and collaboration hubs with universities and hospitals to shorten discovery-to-commercialization timelines.
- Quality escalation: Expanded quality control lines and automated testing to reduce batch variability and improve first-pass yield.
- Customer co‑development: Structured feedback loops and strategic partnerships enabling bespoke reagent formulations and faster regulatory submissions.
- Green manufacturing: Investments in energy-efficient equipment and circular waste treatment systems to lower environmental footprint.
- Ethics & compliance: Strengthened corporate governance, supplier audits, and transparent reporting to maintain stakeholder trust.
Anhui Huaheng Biotechnology Co., Ltd. (688639.SS) DCF Excel Template
5-Year Financial Model
40+ Charts & Metrics
DCF & Multiple Valuation
Free Email Support
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.